Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2014

Open Access 01-12-2014 | Research article

Bu-Zhong-Yi-Qi pill alleviate the chemotherapy-related fatigue in 4 T1 murine breast cancer model

Authors: Mingzi Ouyang, Yanyan Liu, Wei Tan, Ya Xiao, Keqiang Yu, Xiaomin Sun, Ying Huang, JingRu Cheng, Ren Luo, Xiaoshan Zhao

Published in: BMC Complementary Medicine and Therapies | Issue 1/2014

Login to get access

Abstract

Background

Paclitaxel induced fatigue still remains underrecognized and undertreated, partly because of limited understanding of its pathophysiology and lack of effective treatments. This study is aim to evaluate the anti-fatigue effects and mechanism of Bu-Zhong-Yi-Qi pill in murine 4 T1 breast cancer mice were treated with paclitaxel.

Methods

Breast cancer mice established with murine 4 T1 cells were randomly and repectively divided into five groups: negative control group (NC), tumor control group (TC), paclitaxel group (PTX), Bu-Zhong-Yi-Qi pill group (BZYQ) and Bu-Zhong-Yi-Qi pill plus paclitaxel group (BZYQ + PTX). The mice were administered for 21 days. During this period, the tumor volume, body weight and the weight-loaded swimming time were measured. After the last administration, all mice were sacrificed, weighted the tumor, measured immune cell cytokines and oxidative stress indicator. The remaining 10 mice in each group were observed for survival analysis.

Results

Treatments with BZYQ + PTX and PTX significantly reduced the rates of tumor volume in comparison with TC starting on the 9th day and the 18th day respectively (P < 0.05-0.01), and presented decreased tumor weight compared to TC (P < 0.05-0.01). Compared with mice in TC group, the median survival time and the average survival time in BZYQ + PTX group, BZYQ group and PTX group were significantly prolonged (P < 0.05-0.01). The swimming time of the BZYQ + PTX group gradually increased, which is longer than the PTX group on Day 14 and Day 21 (P < 0.01). The level of TNF-α was lower in BZYQ + PTX group than PTX group (P < 0.01). The level of SOD activity in BZYQ + PTX group was lower than the NC group (P <0.01), but much higher than the PTX group (P < 0.01). The level of MDA of BZYQ + PTX group was higher than the NC group (P < 0.01), but significant lower than the PTX group (P < 0.01).

Conclusions

BZYQ has the potential of alleviating paclitaxel chemotherapy-related fatigue in 4 T1 breast cancer mice by reducing the serum levels of TNF-α and modulating the level of MDA and the SOD activity.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009, 59: 225-249. 10.3322/caac.20006.CrossRefPubMed
2.
Ganz PA: Survivorship: adult cancer survivors. Prim Care. 2009, 36: 721-741. 10.1016/j.pop.2009.08.001.CrossRefPubMed
3.
Wang SH, He GP, Jiang PL, Tang LL, Feng XM, Zeng C, Wang GF: Relationship between cancer-related fatigue and personality in patients with breast cancer after chemotherapy. Psychooncology. 2013, 22: 2386-2390.PubMed
4.
Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS, Mulrooney TJ, Schwartz GN, Kaufman PA: Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res. 2007, 33: 323-325.
5.
Alikunju S, Pillarisetti S: Selected players in the inflammation cascade and drugs that target these inflammation genes against metastasis. Anticancer Agents Med Chem. 2006, 66: 461-468.CrossRef
6.
Sood A, Moynihan TJ: Cancer-related fatigue:an update. CurrOncol Rep. 2005, 78: 277-282.
7.
Dimeo FC: Effects of exercise on cancer-related fatigue. Cancer. 2001, 92: 1689-1693. 10.1002/1097-0142(20010915)92:6+<1689::AID-CNCR1498>3.0.CO;2-H.CrossRefPubMed
8.
China PCOT: Pharmacopoeia of the People's Republic of China, Part I. 2005, Beijing: Chemical Industry Press
9.
Tatsumi K, Shinozuka N, Nakayama K, Sekiya N, Kuriyama T, Fukuchi Y: Hochuekkito improves systemic inflammation and nutritional status in elderly patients with chronic obstructive pulmonary disease. J Am Geriatr Soc. 2009, 57: 169-170. 10.1111/j.1532-5415.2009.02034.x.CrossRefPubMed
10.
Chen R, Moriya J, Luo X, Yamakawa J, Takahashi T, Sasaki K, Yoshizaki F: Hochu-ekki-to combined with interferon-gamma moderately enhances daily activity of chronic fatigue syndrome mice by increasing NK cell activity, but not neuroprotection. Immunopharmacol Immunotoxicol. 2009, 31: 238-245. 10.1080/08923970802391525.CrossRefPubMed
11.
Chen R, Moriya J, Yamakawa J, Takahashi T, Li Q, Morimoto S, Iwai K, Sumino H, Yamaguchi N, Kanda T: Brain atrophy in a murine model of chronic fatigue syndrome and beneficial effect of Hochu-ekki-to (TJ-41). Neurochem Res. 2008, 33: 1759-1767. 10.1007/s11064-008-9620-1.CrossRefPubMed
12.
Utsuyama M, Seidlar H, Kitagawa M, Hirokawa K: Immunological restoration and anti-tumor effect by Japanese herbal medicine in aged mice. Mech Ageing Dev. 2001, 122: 341-352.21. 10.1016/S0047-6374(00)00249-9.CrossRefPubMed
13.
Li T, Tamada K, Abe K, Tada H, Onoe Y, Tatsugami K, Harada M, Kubo C, Nomoto K: The restoration of the antitumor T cell response from stress-induced suppression using a traditional Chinese herbal medicine Hochu-ekki-to (TJ-41:Bu-Zhong-Yi-Qi-Tang). Immunopharmacology. 1999, 43: 11-21.22. 10.1016/S0162-3109(99)00034-X.CrossRefPubMed
14.
Harada M, Seta K, Ito O, Tamada K, Li T, Terao H, Takenoyama M, Kimura G, Nomoto K: Concomitant immunity against tumor development is enhanced by the oral administration of a kampo medicine, Hochu-ekki-to (TJ-41: Bu-Zhong-Yi-Qi-Tang). Immunopharmacol Immunotoxicol. 1995, 17: 687-703. 10.3109/08923979509037189.CrossRefPubMed
15.
Ito H, Shimura K: Studies on the antitumor activity of traditional Chinese medicines. Gan To Kagaku Ryoho. 1985, 12: 2145-2148.PubMed
16.
Ito H, Shimura K: Studies on the antitumor activity of traditional Chinese medicines. (II). The antitumor mechanism of traditional Chinese medicines. Gan To Kagaku Ryoho. 1985, 12: 2149-2154.PubMed
17.
Jeong JS, Ryu BH, Kim JS, Park JW, Choi WC, Yoon SW: Bojungikki-tang for cancer-related fatigue: a pilot randomized clinical trial. Integr Cancer Ther. 2010, 9: 331-338. 10.1177/1534735410383170.CrossRefPubMed
18.
Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE: Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res. 2010, 70: 4151-4162. 10.1158/0008-5472.CAN-09-4479.CrossRefPubMed
19.
Porsolt RD, Bertin A, Jalfre M: Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther. 1977, 229: 327-336.PubMed
20.
Ray MA, Trammell RA, Verhulst S, Ran S, Toth LA: Development of a mouse model for assessing fatigue during chemotherapy. Comp Med. 2011, 61: 119-130.PubMedPubMedCentral
21.
Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, Duska LR, Fuller AF, Goodman AK, Nikrui N, MacNeill KM, Matulonis UA, Preffer FI, Seiden MV: Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer. 2000, 10: 33-41.CrossRefPubMed
22.
Collins TS, Lee LF, Ting JP: Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-kappaB-and AP-1 dependent mechanism. Cancer Immunol Immunother. 2000, 49: 78-84. 10.1007/s002620050605.CrossRefPubMed
23.
Lee LF, Li G, Templeton DJ, Ting JP: Paclitaxel(Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase(JNK/SAPK). J Biol Chem. 1998, 273: 2825-3360.
24.
White CM, Martin K, Lee LF, Haskill JS, Ting JP: Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes, and breast cancer cells. Cancer Immunol Immunother. 1997, 46: 10-12.
25.
Bogdan C, Ding A: Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. J Leukoc Biol. 1992, 52: 119-221.PubMed
26.
Janicki-Deverts D, Cohen S, Doyle WJ, Turner RB, Treanor JJ: Infection-induced proinflammatory cytokines are associated with decreases in positive affect, but not increases in negative affect. Brain Behav Immun. 2007, 21: 301-307. 10.1016/j.bbi.2006.09.002.CrossRefPubMed
27.
Vollmer-Conna U, Fazou C, Cameron B, Li H, Brennan C, Luck L, Davenport T, Wakefield D, Hickie I, Lloyd A: Production of pro-inflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans. Psychol Med. 2004, 34: 1289-1297. 10.1017/S0033291704001953.CrossRefPubMed
28.
Huang Y, Henry CJ, Dantzer R, Johnson RW, Godbout JP: Exaggerated sickness behavior and brain proinflammatory cytokine expression in aged mice in response to intracerebroventricular lipopolysaccharide. Neurobiol Aging. 2007, 35: 249-252.
29.
Harden LM, du Plessis I, Poole S, Laburn HP: Interleukin-6 and leptin mediate lipopolysaccharide-induced fever and sickness behavior. Physiol Behav. 2006, 89: 146-155. 10.1016/j.physbeh.2006.05.016.CrossRefPubMed
30.
Stracciari A, Guarino M, Crespi C, Pazzaglia P: Hochuekkito improves systemic inflammation and nutritional status in elderly patients with chronic obstructive pulmonary disease. J Am Geriatr Soc. 2009, 57: 169-170. 10.1111/j.1532-5415.2009.02034.x.CrossRef
31.
Hossain MS, Takimoto H, Hamano S, Yoshida H, Ninomiya T, Minamishima Y, Kimura G, Nomoto K: Protective effects of Hochu-ekki-to, aChinese traditional herbal medicine against murine cytomegalovirus infection. Immunopharmacology. 1999, 41: 169-181. 10.1016/S0162-3109(98)00066-6.CrossRefPubMed
32.
Mori K, Kido T, Daikuhara H, Sakakibara I, Sakata T, Shimizu K, Amagaya S, Sasaki H, Komatsu Y: Effect of Hochu-ekki-to(TJ-41):a Japanese herbal medicine, on the survival of mice infected with influenza virus. Antiviral Res. 1999, 44: 103-111. 10.1016/S0166-3542(99)00048-0.CrossRefPubMed
33.
Abe S, Tansho S, Ishibashi H, Akagawa G, Komatsu Y, Yamaguchi H: Protection of immunosuppressed mice from lethal Candida infection by oral administration of a kampo medicine, Hochu-ekki-to. Immunopharmacol Immunotoxicol. 1999, 21: 331-342. 10.3109/08923979909052766.CrossRefPubMed
34.
Hardin BJ, Campbell KS, Smith JD, Arbogast S, Smith J, Moylan JS, Reid MB: TNF-alpha acts via TNFR1 and muscle-derived oxidants to depress myofibrillar force in murine skeletal muscle. J Appl Physiol. 2008, 104: 694-699. 10.1152/japplphysiol.00898.2007.CrossRefPubMed
35.
Reid MB, Lannergren J, Westerblad H: Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: Involvement of muscle myofilaments. Am J Respir Crit Care Med. 2002, 166: 479-484. 10.1164/rccm.2202005.CrossRefPubMed
36.
Wajant H, Pfizenmaier K, Scheurich P: Tumor necrosis factor signaling. Cell Death Differ. 2003, 10: 45-65. 10.1038/sj.cdd.4401189.CrossRefPubMed
37.
Powers SK, Jackson MJ: Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production. Physiol Rev. 2008, 88: 1243-1276. 10.1152/physrev.00031.2007.CrossRefPubMedPubMedCentral
38.
Supinski GS, Callahan LA: Free radical-mediated skeletal muscle dysfunction in inflammatory conditions. J Appl Physiol. 2007, 102: 2056-2063. 10.1152/japplphysiol.01138.2006.CrossRefPubMed
39.
Chen Y, Jungsuwadee P, Vore M, Butterfield DA, St Clair DK: Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interv. 2007, 7: 47-156.CrossRef
40.
Muinelo-Romay L, Alonso-Alconada L, Alonso-Nocelo M, Barbazan J, Aba M: Tumor invasion and oxidative stress: biomarkers and therapeutic strategies. Curr Mol Med. 2012, 12: 1566-5240.CrossRef
41.
Akbas SH, Timur M, Ozben T: The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells. J Surg Res. 2005, 125: 49-55. 10.1016/j.jss.2004.11.011.CrossRefPubMed
42.
Mohamed HE, Asker ME, Ali SI, el-Fattah TM: Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4. J Pharm Pharmacol. 2004, 56: 757-768. 10.1211/0022357023565.CrossRefPubMed
43.
Seyhan N, Canseven AG: In vivo effects of ELF MFs on collagen synthesis, free radical processes, natural antioxidant system, respiratory burst system, immune system activities, and electrolytes in the skin, plasma, spleen, lung, kidney, and brain tissuess. Electromagn Biol Med. 2006, 25: 291-305. 10.1080/15368370601054787.CrossRefPubMed
44.
Suzer T, Coskun E, Demir S, Tahta K: Lipid peroxidation and glutathione levels after cortical injection of ferric chloride in rats: effect of trimetazidine and deferoxamine. Res Exp Med (Berl). 2000, 199: 223-229.
45.
Lee MY, Shin IS, Jeon WY, Seo CS, Ha H, Huh JI, Shin HK: Protective effect of Bojungikki-tang, a traditional herbal formula, against alcohol-induced gastric injury in rats. J Ethnopharmacol. 2012, 142: 346-353. 10.1016/j.jep.2012.04.043.CrossRefPubMed
46.
Li X, Wang X, Han C, Wang X, Xing G, Zhou L, Li G, Niu Y: Astragaloside IV suppresses collagen production of activated HSCs via oxidative stress-mediated p38 MAPK pathway. Free Radic Biol Med. 2013, 60: 168-76.CrossRefPubMed
47.
Abe H, Sakaguchi M, Yamada M, Arichi S, Odashima S: Pharmacological actions of saikosaponins isolated from Bupleurum falcatum. 1. Effects of saikosaponins on liver function. Planta Med. 1980, 40: 366-372. 10.1055/s-2008-1074987.CrossRefPubMed
48.
Matsumoto T, Sun XB, Hanawa T, Kodaira H, Ishii K, Yamada H: Effect of the antiulcer polysaccharide fraction from Bupleurum falcatum L. on the healing of gastric ulcer induced by acetic acid in rats. Phytother Res. 2002, 16: 91-93.CrossRefPubMed
49.
Chang WC, Hsu FL: Inhibition of platelet activation and endothelial cell injury by flavan-3-ol and saikosaponin compounds. Prostaglandins Leukot Essent Fatty Acids. 1991, 44: 51-56. 10.1016/0952-3278(91)90144-T.CrossRefPubMed
50.
Nose M, Amagaya S, Ogihara Y: Corticosterone secretion-inducing activity of saikosaponin metabolites formed in the alimentary tract. Chem Pharm Bull (Tokyo). 1989, 37: 2736-2740. 10.1248/cpb.37.2736.CrossRef
51.
Abe H, Sakaguchi M, Odashima S, Arichi S: Protective effect of saikosaponin-d isolated from Bupleurum falcatum L. on CCl4-induced liver injury in the rat. Naunyn Schmiedebergs Arch Pharmacol. 1982, 320: 266-271. 10.1007/BF00510139.CrossRefPubMed
52.
Hattori T, Ito M, Suzuki Y: Studies on antinephritic effects of plant components in rats (2): Effects of ginsenosides on original-type anti-GBM nephritis in rats and its mechanisms. Nihon Yakurigaku Zasshi. 1991, 97: 127-134. 10.1254/fpj.97.2_127.CrossRefPubMed
53.
Grabiec K, Burchert M, Milewska M, Błaszczyk M, Grzelkowska-Kowalczyk K: Systemic and local mechanisms leading to cachexia in cancer. Postepy Hig Med Dosw. 2013, 67: 1397-1409.CrossRef
54.
Abaid LN, Lopez KL, Micha JP, Rettenmaier MA, Brown JV, Goldstein BH: Bevacizumab, paclitaxel and carboplatin for advanced ovarian cancer: low risk of gastrointestinal and cardiovascular toxicity. Eur J Gynaecol Oncol. 2010, 31: 308-311.PubMed
55.
Kim HJ, Seo JY, Suh HJ, Lim SS, Kim JS: Antioxidant activities of licorice-derived prenylflavonoids. Nutr Res Pract. 2012, 6: 491-498. 10.4162/nrp.2012.6.6.491.CrossRefPubMedPubMedCentral
Metadata
Title
Bu-Zhong-Yi-Qi pill alleviate the chemotherapy-related fatigue in 4 T1 murine breast cancer model
Authors
Mingzi Ouyang
Yanyan Liu
Wei Tan
Ya Xiao
Keqiang Yu
Xiaomin Sun
Ying Huang
JingRu Cheng
Ren Luo
Xiaoshan Zhao
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2014
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/1472-6882-14-497

Other articles of this Issue 1/2014

BMC Complementary Medicine and Therapies 1/2014 Go to the issue

Research article

New perspectives on patient expectations of treatment outcomes: results from qualitative interviews with patients seeking complementary and alternative medicine treatments for chronic low back pain

Research article

Palm kernel cake extract exerts hepatoprotective activity in heat-induced oxidative stress in chicken hepatocytes

Research article

Effects of astragalus injection on the TGFβ/Smad pathway in the kidney in type 2 diabetic mice

Research article

Anti-invasive effects of Celastrus Orbiculatus extract on interleukin-1 beta and tumour necrosis factor-alpha combination-stimulated fibroblast-like synoviocytes

Research article

Which tree orders in southern Africa have the highest antimicrobial activity and selectivity against bacterial and fungal pathogens of animals?

Research article

Antitumor effect of Kanglaite® injection in human pancreatic cancer xenografts